GPT and metabolic dysfunction-associated steatotic liver disease: Metabolic profile performed similar or better than other markers for predicting fibrosis progression: ALT (AUROC 0.69, 95% CI: 0.55–0.84, p = 0.016), AST (AUROC 0.75, 95% CI: 0.62–0.89, p = 0.001), FIB-4 (AUROC 0.55, 95% CI: 0.40–0.71, p = 0.5), NAFLD fibrosis score (AUROC 0.42, 95% CI: 0.26–0.58, p = 0.32) and LSM at baseline (AUROC 0.41, 95% CI: 0.25–0.59, p = 0.3) (Figure 2).